7/109 sources · 3 publishersUpdated Nov 3, 14:32 UTC
Travere Therapeutics reports Q3 2026 loss and revenue beat amid high R&D spend
Travere Therapeutics announced its third‑quarter 2026 results, posting a loss of $0.55 per share on revenue of $224.56 million. The miss was driven by a $113.1 million research and development expense, while its rare‑kidney drug Filspari generated strong sales growth. The company also disclosed that CEO Eric Dube will step down on December 1, 2026, and that a patent notice extends Filspari’s protection to 2037.
Why it matters
Leerink Partners cut its price target to $67 from $78 after the earnings miss, and the stock fell 4.3% in pre‑market trading. The high R&D spend and leadership change add uncertainty to near‑term profitability.
Key facts
- 1Q3 2026 earnings per share were a loss of $0.55. investing.com
- 2Revenue for the quarter was $224.56 million. investing.com
- 3Research and development expense was $113.1 million. investing.com
- 4Filspari sales grew 120% year‑over‑year. investing.com
- 5CEO Eric Dube will step down on December 1, 2026. investing.com
- 6A Notice of Allowance extends Filspari’s patent protection to October 2037. investing.com
Open questions
- Filspari quarterly net product sales are reported as $200.2 million and $8 million, a conflict on the same metric.
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.